Obesity Update: Enobosarm’s Oral Release, AI-Powered Drug Discovery, £85M UK-Lilly Obesity Plan, Wegovy’s Price Cut & More
In this week’s Obesity Updates, we spotlight pivotal developments reshaping the global obesity treatment landscape—from next-gen GLP-1 alternatives and AI-led discovery to strategic price positioning and bold government-industry partnerships.
🔬 Key Highlights This Week:
💊 Veru reveals a novel oral formulation of enobosarm for weight loss
🧪 Lexaria wraps up clinical phase in its GLP-1 trial
🇬🇧 Lilly and the UK government roll out an £85M obesity care programme
🧠 Biogen eyes a potential Alzheimer’s–obesity treatment combo
🤖 Lilly inks a $1.3B deal to discover obesity drugs using AI
🇰🇷 Novo Nordisk cuts Wegovy prices in Korea by up to 40%
🚀 Lilly launches Mounjaro in Korea with dual-agonist action and competitive pricing
From regulatory milestones to price wars and global partnerships, this update covers everything you need to stay ahead in the rapidly evolving obesity treatment landscape.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on Obesity
#ObesityResearch #GLP1 #Enobosarm #Mounjaro #Wegovy #Lilly #NovoNordisk #Biogen #HealthcareInnovation #AIinPharma #WeightLossDrugs #LucidQuest